GSK – Discontinuation of Blenrep® (belantamab mafodotin-blmf)
November 22, 2022 - GSK announced the market withdrawal of Blenrep (belantamab mafodotin-blmf) following the request of the FDA. This request was based on the previously announced outcome of the DREAMM-3 phase III confirmatory trial, which did not meet the requirements of the FDA Accelerated Approval regulations.
Top